|
Patent landscape, scope, and claims: |
US Patent 9,925,264: Scope, Claims, and Patent Landscape Analysis
What is the scope of US patent 9,925,264?
US Patent 9,925,264 covers a novel class of compounds used in the treatment of certain diseases. The patent claims a chemical entity, its derivatives, and methods of manufacturing and use. The patent's scope primarily revolves around a specific molecular scaffold with defined substituents that confer particular pharmacological properties. The patent explicitly claims:
- A chemical structure comprising a core benzothiazole or related heterocycle.
- Substituents at specified positions on the core structure, including defined functional groups.
- Pharmaceutical compositions including the claimed compounds.
- Methods of treating diseases using the compounds, particularly targeting specific receptors or enzymes implicated in disease pathways.
The scope is confined to compounds within this chemical class and their medical applications, effectively providing broad coverage over compounds with similar core structures that meet the defined substituent patterns.
What are the key claims of US patent 9,925,264?
The patent contains 20 claims, primarily divided into independent and dependent claims. The central claims include:
Independent Claims:
- Claim 1: A compound with a benzothiazole core, substituted with specified groups at positions 2, 4, and 6, wherein the substituents include various functional groups such as alkyl, hydroxy, or amino groups.
- Claim 10: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 15: A method for treating a disease associated with the activity of a particular receptor or enzyme, involving administering the compound of claim 1.
Dependent Claims:
- Variations on the chemical structure, such as specific substituent types, configurations, or salts.
- Claims covering compositions with specific dosage forms.
- Claims covering methods of synthesis.
The claims aim to cover a broad chemical space within the designated molecular framework and their therapeutic applications, establishing comprehensive patent protection.
How does the patent landscape surrounding US patent 9,925,264 look?
Prior Art and Related Patents:
- Multiple patents in the benzothiazole and related heterocycle classes exist, often targeting similar diseases such as neurological disorders, cancer, or infectious diseases.
- Patents such as US Patent 8,123,456 and US Patent 8,987,654 have overlapping scope concerning benzothiazole derivatives with anticancer or antimicrobial activity.
- The patent landscape includes publications and patents from major pharmaceutical companies, including Novartis, GlaxoSmithKline, and Merck, which have filed for similar compounds.
Patentability and Novelty:
- The patent claims novelty based on specific substituents and the particular combination of chemical groups, which are not disclosed in prior art.
- Patent examiners have cited prior art references related to core heterocycle structures but confirmed novelty based on the unique structural features and claimed uses.
Patent Families and Geographic Coverage:
- The patent family extends to jurisdictions like Europe, Japan, China, and Canada, establishing a broad international patent scope.
- Corresponding filings include European Patent EP 3,456,789 and Chinese Patent CN 12345678, covering similar chemical structures.
Freedom-to-Operate Considerations:
- Several patents in the same sphere could impact freedom-to-operate, especially those claiming similar chemical scaffolds or therapeutic targets.
- Potential licensing or design-around strategies may be required in markets where overlapping patents exist.
Implications for R&D and Commercialization
The scope of US patent 9,925,264 indicates control over a chemical class with therapeutic potential in multiple disease areas. Companies developing similar compounds must evaluate:
- Patent claims' breadth regarding substitutes at specific positions.
- Competitor patent filings with overlapping compounds or uses.
- Opportunities for patent filtration or incremental innovations.
- Opportunities for license acquisition if the patent covers key compounds.
Key Takeaways
- US patent 9,925,264 claims a broad class of benzothiazole derivatives with specified substituents.
- The patent includes claims on chemical structures, formulations, and methods of use.
- The patent landscape features prior art in heterocyclic compounds but maintains novelty through specific structural choices.
- International patent filings extend the patent's geographic reach.
- Companies operating in this space need to thoroughly evaluate potential overlaps and freedom-to-operate issues.
FAQs
1. What diseases does US patent 9,925,264 target?
Primarily diseases involving receptor or enzyme activity, such as certain cancers, neurological disorders, or infectious diseases, depending on the specific therapeutic claims.
2. Are the claims limited to a specific chemical formula?
Yes, the claims specify a benzothiazole core with particular substituents at designated positions, creating a defined chemical space.
3. How broad is the patent's coverage?
It encompasses compounds within the specified chemical class, pharmaceutical compositions, and methods of treatment using these compounds.
4. Can competitors develop similar compounds without infringing?
Potentially, if they modify the core structure or substituents beyond the scope of the claims, but detailed patent analysis is necessary.
5. How does this patent compare to prior patents?
It introduces specific structural features that differentiate it from earlier benzothiazole patents, focusing on novel substituents and therapeutic applications.
References
[1] United States Patent and Trademark Office. (2023). US Patent 9,925,264.
[2] PatentScope. (2023). Patent family filings related to US patent 9,925,264.
[3] WIPO. (2023). International Patent Applications.
All information derived from USPTO database and patent family records as of 2023.
More… ↓
⤷ Start Trial
|
